Abstracts Archive - Page 3 of 2616 - ACR Meeting Abstracts

Abstract Number: 026 • 2026 Pediatric Rheumatology Symposium
Treatment strategies for articular flares in JIA patients receiving biologic therapy
Jonatan zalcman, Yoel Levinsky, Liora Harel, Ruth Livny and gil amarilyo, Schneider Children's medical center of Israel
Background/Purpose: Biologic agents form the cornerstone of therapy for Juvenile Idiopathic Arthritis (JIA); however, the optimal management of flares that occur during ongoing treatment remains…
Abstract Number: 005 • 2026 Pediatric Rheumatology Symposium
Magnetic Resonance Enterography Detected Sacroiliitis in Pediatric Crohn’s Disease: A Retrospective Cohort Study
Aaisham Ali¹, Vishal Kalia², Ian Ross², Luke Daichendt³, Julia Sawicka⁴, Michael R Miller⁵, Sarah Wells⁶, Eileen Crowley⁶ and Roberta A Berard⁷, ¹Schulich School of Medicine & Dentistry, Pediatrics, London Health Sciences Centre, London, ON, Canada, ²Department of Medical Imaging, Western University, ³Schulich School of Medicine & Dentistry, Western University, ⁴Western University, ⁵Department of Pediatrics, Children's Hospital, London Health Sciences Centre, ⁶London Children's Hospital, ON, Canada, ⁷London Health Sciences Centre, London, ON, Canada
Background/Purpose: Musculoskeletal (MSK) manifestations are amongst the most common extraintestinal manifestations (EIMs) in pediatric Crohn’s disease (CD). MSK EIMs contribute to reduced quality of life…
Abstract Number: 010 • 2026 Pediatric Rheumatology Symposium
Efficacy and Safety of Emapalumab in Patients with Macrophage Activation Syndrome (MAS) in Systemic Lupus Erythematosus (SLE)
Alexei Grom¹, Shoghik Akoghlanian², melissa elder³, Renee Modica⁴, Steve Mallett⁵, Brian D. Jamieson⁶ and Fabrizio De Benedetti⁷, ¹Cincinnati Children’s Hospital, Division of Rheumatology, Cincinnati, OH, ²Nationwide Childrens Hospital, Columbus, OH, ³Division of Allergy, Immunology, and Rheumatology, Department of Pediatrics, University of Florida, GAINESVILLE, FL, ⁴Division of Allergy, Immunology, and Rheumatology, Department of Pediatrics, University of Florida, Orlando, FL, ⁵Sobi, ⁶Sobi, Inc., ⁷Bambino Gesu Children's Hospital, Rome, Rome, Italy
Background/Purpose: MAS is a life-threatening complication of SLE, characterized by interferon-gamma (IFNg)-driven macrophage activation and systemic hyperinflammation. There is substantial preclinical evidence of IFNg having…
Abstract Number: 002 • 2026 Pediatric Rheumatology Symposium
Assessing Juvenile Idiopathic Arthritis Healthcare Costs to Advance Value-Based Care
Julia Harris¹, Luke Harris², Kristy Diederich³, Rachel Moran³, Emily Fox², Leslie Favier⁴, Stephanie Quinn³ and ashley cooper², ¹Children's Mercy Kansas City, Overland Park, KS, ²Children's Mercy Kansas City, Kansas City, MO, ³Children's Mercy Kansas City, ⁴Children's Mercy Kansas City, Leawood, KS
Background/Purpose: Despite treatment advances and continued quality improvement efforts, outcomes for our patients with juvenile idiopathic arthritis (JIA) remain suboptimal. To address this challenge, we…
Abstract Number: 012 • 2026 Pediatric Rheumatology Symposium
Prevalence and Impact of Adverse Childhood Experiences in Pediatric Systemic Lupus Erythematosus
Anita Dhanrajani¹, Rhea Bhargava² and Alfred Kim³, ¹Manning Family Children's Hospital, Tulane University, ²Tulane University Medicine, New Orleans, LA, ³Washington University School of Medicine, Saint Louis, MO
Background/Purpose: Adverse childhood experiences (ACEs) have been linked to incident childhood-onset SLE (cSLE) and poorer patient-reported outcomes, raising the possibility that early-life stress may contribute…
Abstract Number: 016 • 2026 Pediatric Rheumatology Symposium
Still’s Disease Associated Lung Disease: Experience from a Tertiary Italian Centre
Claudia Bracaglia¹, Manuela Pardeo², Matteo Trevisan², Arianna De Matteis², Ivan Caiello³, Giusi Prencipe³ and Fabrizio De Benedetti⁴, ¹Division of Rheumatology Ospedale Pediatrico Bambino Gesu' IRCCS, Roma, Italy, Rome, Rome, Italy, ²Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy, Rome, Lazio, Italy, ³Laboratory of Immuno-Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy, Rome, Lazio, Italy, ⁴Bambino Gesu Children's Hospital, Rome, Rome, Italy
Background/Purpose: Still’s Disease (SD)-associated lung disease (SD-LD) is a severe potentially life-threatening condition characterized by peculiar features. For the rarity of this condition, the experience…
Abstract Number: 043 • 2026 Pediatric Rheumatology Symposium
Challenges of Cognitive Screening and Formal Neuropsychological Evaluation in Youth with Childhood-Onset Systemic Lupus Erythematosus: A Survey of CARRA Providers
Ryan Kammeyer¹, Martha Rodriguez², Andrea Knight³, Rebecca Sadun⁴, Jeffrey Bennett⁵, Robert Fuhlbrigge⁶, Christa Hutaff-Lee⁵ and Ekemini Ogbu⁷, ¹Departments of Pediatrics and Neurology, University of Colorado School of Medicine, Aurora, CO, ²Riley Hospital For Children At Indiana University, Carmel, IN, ³Hospital for Sick Children, Toronto, ON, Canada, ⁴Duke University School of Medicine, Durham, NC, ⁵University of Colorado School of Medicine, ⁶University of Colorado, Aurora, CO, ⁷Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Cognitive dysfunction (CD) occurs in 30-60% of youth with childhood-onset systemic lupus erythematosus (cSLE), and negatively impacts medical care, socioeconomic achievement, and quality of…
Abstract Number: 003 • 2026 Pediatric Rheumatology Symposium
Dysregulated Macrophage–Fibroblast Crosstalk Identified by Single-Cell RNA-seq in Juvenile Systemic Scleroderma Skin
Aneri Shethji¹, Theresa Hutchins¹, Anwesha Sanyal¹ and Kathryn Torok², ¹UPMC Childrens Hospital of Pittsburgh, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Juvenile systemic scleroderma (jSSc) is a rare autoimmune disease characterized by progressive fibrosis and vascular dysfunction. Although jSSc shares important clinical features with adult…
Abstract Number: 042 • 2026 Pediatric Rheumatology Symposium
Mindfulness Matters: Early Insights from the Making Mindfulness Matter© in children with Juvenile Idiopathic Arthritis Study.
Roberta A Berard¹, KAREN BEATTIE², Sarah Wells³, Michelle Batthish⁴, Asha Jeyanathan⁵, Frances Montemurro⁶, Karen Bax⁷ and Andrea Knight⁸, ¹London Health Sciences Centre, London, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³London Children's Hospital, ON, Canada, ⁴McMaster Children's Hospital, Hamilton, ON, Canada, ⁵Hospital for Sick Children, ON, Canada, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷Adjunct Professor, Psychology, Western Ontario, ON, Canada, ⁸Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Poor mental health (MH) in the pediatric rheumatology population has been shown to affect quality of life, educational attainment, and disease-related outcomes, such as…
Abstract Number: 025 • 2026 Pediatric Rheumatology Symposium
Longitudinal Single Cell Transcriptomic Analysis of Type I and II Interferon (IFN) Response Genes (IRG) in Refractory Juvenile Dermatomyositis (JDM) Patients with Baricitinib Treatment
Jessica Simpson¹, Vicky Chen², Adeline Chin³, Ujana Zajmi³, Amy Kaneshiro³, Megan Darrell⁴, Stephen Brooks³, Robert Colbert⁵, Lisa Rider⁶, Stefania Dell’Orso³, Faiza Naz³ and Hanna Kim⁷, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)/National Institutes of Health (NIH), ²National Institute of Allergy and Infectious Diseases (NIAID)/ National Institutes of Health (NIH), Frederick, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) / National Institutes of Health (NIH), ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) / National Institutes of Health (NIH), NY, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) / National Institutes of Health (NIH), Rockville, MD, ⁶National Institute of Environmental Health Sciences (NIEHS)/National Institutes of Health (NIH), ⁷National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS) / National Institutes of Health (NIH)
Background/Purpose: JDM is a rare heterogenous autoimmune condition. Pathogenesis is incompletely understood, though dysregulated type I/II IFN signaling is well-documented. Patients with refractory JDM had…
Abstract Number: 006 • 2026 Pediatric Rheumatology Symposium
Age Matters: Clinical Profile and IVIG Responsiveness in infants with Kawasaki Disease. A multicentric retrospective analysis of 36 patients from North India
Abhay Shivpuri¹, manjari Agarwal² and sujata Sawhney³, ¹Neoclinic Children's Hospital, Jaipur, Rajasthan, India, ²Sir Ganga Ram Hospital, NEW DELHI, Delhi, India, ³Sir Ganga Ram Hospital, Sector ³⁷ noida, Uttar Pradesh, India
Background/Purpose: Kawasaki disease (KD) is a systemic medium vessel vasculitis that is predominantly a clinical diagnosis as defined by the American Heart Association (AHA). KD…
Abstract Number: 028 • 2026 Pediatric Rheumatology Symposium
Are You Positive About this Positive ANA Referral? Outcomes for ANA Based Referrals to Pediatric Rheumatology and Subsequent Disease Development
Josh Umland¹, Elizabeth Volkmann², Annabelle Lee³, Nicholas Jackson², Deborah McCurdy⁴, Alice Hoftman⁵, Miriam Parsa⁶, John Fitzgerald⁷ and Alexis Stephens⁸, ¹UCLA, ²University of California, Los Angeles, Los Angeles, CA, ³UCLA Department of Medicine Statistics Core, San Diego, CA, ⁴UCLA Medical Center, Los Angeles, CA, ⁵David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁶Cottage Childrens Medical Center, SANTA BARBARA, CA, ⁷UCLA, Los Angeles, CA, ⁸University of California, Los Angeles
Background/Purpose: ANA positivity is a frequent finding in pediatric rheumatology referrals, but infrequently reflects underlying autoimmune disease. Earlier studies found that most ANA positive patients…
Abstract Number: 041 • 2026 Pediatric Rheumatology Symposium
Pediatric Behçet’s Disease: A 13-Year Single-Center Experience Highlighting Diagnostic Delays and High Neurological Burden
Rasha Elrefai¹, Andrea Ramirez¹, Jamie Lai², Cagri Yildirim-Toruner³, Eyal Muscal¹ and Marietta DeGuzman¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, The Woodlands, TX, ³Texas Children's Hospital/ Baylor College of Medicine, Houston, TX
Background/Purpose: Behçet's disease (BD) is a systemic vasculitis primarily characterized by recurrent oral and genital aphthous ulceration. It is reported that 15-20% of all BD…
Abstract Number: 034 • 2026 Pediatric Rheumatology Symposium
Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Management Across Countries: A Survey to Inform Future Comparative Effectiveness Research
Mehmet YILDIZ¹, Samira Nazzar Romero², Lakshmi Moorthy³, Edan Itzkovitz⁴, Halide Ozge Basaran⁵, Tara Lozy⁶, Patricia DeLaMora⁷, Tatjana Welzel⁸, Ruby Haviv⁹, Kalpana Manthiram¹⁰, Camilo Vargas¹¹, Erdal Sag¹², amit ziv¹³, Adi Pappo¹⁴, Özlem Satirer¹⁵, Maryam Piram¹⁶, Gülşah Kavrul Kayaalp¹⁷, Nuray Aktay Ayaz¹⁸, Antonella Insalaco¹⁹, Jasmin Kuemmerle-Deschner²⁰, Dilan Dissanayake⁴, Kader Cetin Gedik²¹, Nadine Saad²², Nataša Toplak²³, Ozgur Kasapcopur²⁴, Marinka Twilt²⁵, Isabelle koné-Paut²⁶, Ronald M. Laxer²⁷, Marco Gattorno²⁸, Seza zen²⁹, Fatma Dedeoglu³⁰ and Sivia Lapidus³¹, ¹Division of Pediatric Rheumatology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Turkey, ²Division of Rheumatology, Nemours Children's Health, University of Central Florida College of Medicine, Orlando, United States, Orlando, FL, ³Department of Pediatrics, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, United States, Metuchen, NJ, ⁴Division of Rheumatology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Canada, Toronto, ON, Canada, ⁵Department of Pediatrics, Hacettepe University, Ankara, Türkiye, New York City, NY, ⁶Joseph M. Sanzari Children's Hospital, Hackensack Meridian Health, Center for Discovery and Innovation, Hackensack Meridian Health and Hackensack Meridian School of Medicine, ⁷Department of Pediatrics, School of Medicine, New York Medical College, Valhalla, United States, ⁸Pediatric Rheumatology, University Children's Hospital Basel (UKBB), University of Basel, Basel, Switzerland, ⁹Pediatric Rheumatology Unit, Department of Pediatrics, Meir Medical Center, Kfar Saba, Israel., ¹⁰Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Bethesda, United States, Bethesda, MD, ¹¹Faculty of Medicine, Universidad del Valle, Cali, Colombia, Cali, Colombia, ¹²Department of Pediatric Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, and Division, Ankara, Turkey, ¹³Pediatric Rheumatology Unit, Department of Pediatrics, Meir Medical Center, Kfar Saba, Israel, herzelia, Israel, ¹⁴Pediatric Rheumatology Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel, HaMerkaz, Israel, ¹⁵Department of Paediatrics and Autoinflammation reference Center Tuebingen (arcT), Universitatsklinikum Tubingen, Tubingen, Baden-Württemberg, Germany, ¹⁶Department of Pediatrics, CHU Sainte-Justine, Université de Montréal, Montreal, QC, Canada; CHU Sainte-Justine Research Center, Université de Montréal, Montreal, QC, Canada, Montral, Canada, ¹⁷Department of Pediatric Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ¹⁸Department of Pediatric Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, Istanbul, Turkey, ¹⁹Division of Rheumatology, ERN RITA Center, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ²⁰Department of Paediatrics and Autoinflammation reference Center Tuebingen (arcT), Universitatsklinikum Tubingen, Tubingen, Baden-Württemberg, Germany, Tuebingen, Germany, ²¹Division of Pediatric Rheumatology, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; Pediatric Autoinflammatory Diseases Center, University of Pittsburgh, Pittsburgh, United States, Pittsburgh, PA, ²²University of Michigan, Michigan Medicine, Ann Arbor, Michigan, United States, Ann Arbor, MI, ²³Department of Allergology, Rheumatology and Clinical Immunology, University Children's Hospital, Ljubljana, Slovenia, ²⁴Istanbul University-Cerrahpasa, Department of Pediatric Rheumatology, Istanbul, Türkiye, istanbul, Turkey, ²⁵Alberta Children's Hospital, Calgary, AB, Canada, ²⁶Department of Pediatrics, Kremlin-Bicêtre University Hospital, Paris-Saclay University, Paris, France, ²⁷The Hospital for Sick Children, Toronto, ON, Canada, ²⁸Division of Rheumatology and Autoinflammatory Diseases, IRCCS Istituto Giannina Gaslini, Genoa, Italy, Genova, Italy, ²⁹Hacettepe University Medical Faculty, Ankara, Turkey, ³⁰Boston Children's Hospital, Boston, MA, ³¹Joseph M. Sanzari Children's Hospital, Hackensack Meridian Health, Center for Discovery and Innovation, Hackensack Meridian Health and Hackensack Meridian School of Medicine, Montclair, NJ
Background/Purpose: Background: PFAPA is the most common autoinflammatory condition of childhood. Its frequency, clinical features, and response to treatments vary across populations. To standardize care, the…
Abstract Number: 021 • 2026 Pediatric Rheumatology Symposium
Medication Changes and Lung Disease Activity in Systemic JIA: Six-Month Follow-Up of CARRA Registry SJIA-LD Cohort
Grant Schulert¹, Eileen Rife², Mary Ellen Riordan³, Alan Russell⁴, Mei-Sing Ong⁵, Esraa Eloseily⁶, Lexi Auld⁷, Yukiko Kimura⁸, and CARRA Registry SJIA-LD Cohort Investigators ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²University of Alabama Birmingham, Vestavia Hills, AL, ³Hackensack University Medical Center, Westwood, NJ, ⁴Duke Clinical Research Institute, NC, ⁵Boston Children's Hospital, Boston, MA, ⁶UT Southwestern Children's Medical Center, Dallas, TX, ⁷Cincinnati Children's Hospital Medical Center, OH, ⁸Hackensack Meridian School of Medicine, New York, NY
Background/Purpose: Lung disease is a severe and potentially fatal complication of systemic juvenile idiopathic arthritis (SJIA-LD). The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].